
Veracyte (VCYT) Stock Forecast & Price Target
Veracyte (VCYT) Analyst Ratings
Bulls say
Veracyte Inc reported a strong financial performance with a non-GAAP operating margin of 28.8%, reflecting an increase of 830 basis points year-over-year, alongside an adjusted EBITDA margin of 30.1%, which was up 650 basis points year-over-year. The company experienced robust growth in genomic test volume, achieving approximately 45,888 tests, a growth rate of 18%, with notable contributions from Decipher prostate tests and Afirma thyroid tests, which both set new records. Additionally, Veracyte's management increased the adjusted EBITDA margin guidance for 2025 to approximately 25.0%, a significant improvement over the previous year's performance, indicating a positive trajectory for profitability moving forward.
Bears say
Veracyte faces significant risks related to weaker-than-expected sales from its Decipher and Afirma tests, which could adversely impact its operating margins and free cash flow. Recent financial metrics show a decline in revenue per test and a projected decrease in adjusted EBITDA margins for 2026, indicating potential challenges in profitability. Additionally, while test volume growth remains positive, it has slowed compared to previous periods, suggesting a risk to sustained revenue growth, compounded by the concern of overall market performance falling short of expectations.
This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.
Veracyte (VCYT) Analyst Forecast & Price Prediction
Start investing in Veracyte (VCYT)
Order type
Buy in
Order amount
Est. shares
0 shares